|The following article features coverage from the SGO 2022 Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor’s conference coverage.|
Patients with gynecologic cancers may have a high risk of hospitalization and death from COVID-19, according to new data presented at the SGO 2022 Annual Meeting on Women’s Cancer.
In a registry-based study, 5% of patients with gynecologic cancer died within 30 days of being diagnosed with COVID-19.
“This is concerning on its own, given the overall US case-fatality rate of 1.6%, but even more so given the fact that this study spanned the time before and during vaccine availability and included several emerging treatment approaches,” said Gretchen Glaser, MD, of the Mayo Clinic in Rochester, Minnesota, when presenting these data at the meeting.
Dr Glaser and colleagues conducted this study using the Society of Gynecologic Oncology COVID-19 and Gynecologic Cancer Registry.
Data were available for 348 patients from 7 institutions in 6 states (Minnesota, New York, Pennsylvania, Tennessee, Louisiana, and Nebraska). The practice type was 99% urban and 81% academic tertiary care.
In all, 36% of patients had active cancer at COVID-19 diagnosis, and 24% were receiving anticancer treatment. Cancer types included endometrial, ovarian, cervical, and vulvar cancer. The most common treatments were surgery (43%) and chemotherapy (32%), and 14% of patients were receiving multimodal therapy.
Delays or discontinuation of treatment due to COVID-19 occurred in 28% of patients. The median delay was 3 to 4 weeks. Chemotherapy was the most frequently delayed treatment, followed by surgery, Dr Glaser said.
Outcomes: Hospitalization and Death
Overall, 29% of patients were hospitalized, 20% required supplemental oxygen, and 5% were admitted to the ICU. COVID-19 treatments included monoclonal antibodies, convalescent plasma, corticosteroids, antibiotics, antiviral medications, and hydroxychloroquine.
Eight percent of hospitalized patients and 5% of the entire cohort died within 30 days of COVID-19 diagnosis.
In a multivariate analysis, factors significantly associated with hospitalization were age at COVID-19 diagnosis (odds ratio [OR], 1.17; P =.006), diabetes mellitus (OR, 2.81; P =.003), pulmonary embolism (OR, 3.55; P =.02), active malignancy (OR, 2.26; P =.009), and non-White race (OR, 2.95; P =.001).
Factors associated with an increased risk of death within 30 days in a multivariate analysis were older age (OR, 1.27 per 5-year increase; 95% CI, 1.03-1.57) and active malignancy (OR, 6.18; 95% CI, 1.91-1.94).
Dr Glaser said additional studies are warranted to determine the long-term outcomes and the impact of race in gynecologic cancer patients with COVID-19.
Disclosures: Dr Glaser reported having no conflicts of interest.
Read more of Cancer Therapy Advisor’s coverage of SGO 2022 by visiting the conference page.
Glaser G, Lara O, Pothuri B, et al. Impact of COVID-19 on gynecologic oncology patients: An SGO COVID-19 and Gynecologic Cancer Registry study. Presented at SGO 2022; March 18-21, 2022. Abstract 50.